What Happens If You Don't Report Cosmetic Adverse Events to the FDA

The form used to report a serious cosmetic adverse event is small. The enforcement problem created by missing it is not. MoCRA treats serious-event reporting, adverse-event records, and the label intake channel as legal obligations. When one complaint reveals that a Responsible Person has no working process, the FDA is no longer looking at a late email; it is looking at whether the product and the business are operating in compliance with the Federal Food, Drug, and Cosmetic Act.

The first problem: a prohibited act and a potentially misbranded product

Failing to submit a required serious adverse event report or provide required records can constitute a prohibited act. Separately, a cosmetic label that lacks the required domestic address, domestic telephone number, or electronic contact information can make the product misbranded. Those are not abstract classifications. An imported cosmetic that appears adulterated, misbranded, or otherwise violative may be refused admission under the FDA's import authority.

How the enforcement ladder reaches a foreign brand

A first incident may lead to questions, a records request, or an inspection observation. If the label itself is noncompliant or the product appears violative, an incoming shipment can be detained while the importer tries to produce evidence. Repeated violations, unreliable responses, or a wider safety concern can support an import alert, which allows future shipments to be detained without physical examination. At that point, the burden and cost move to the importer and brand: storage, testing, reconditioning, re-export, or destruction while sales stop.

MoCRA also gave the FDA stronger domestic-market tools. The agency may suspend a cosmetic facility's registration when the statutory serious-health-risk conditions are met and the problem is sufficiently connected to the facility. Distribution from a suspended facility is prohibited. The FDA may order a mandatory recall when it determines that an adulterated or misbranded cosmetic presents the required probability of serious adverse health consequences or death and the Responsible Person does not voluntarily recall it. These powers have specific legal thresholds, but a missing adverse-event system makes a brand far less able to demonstrate control when the FDA evaluates the risk.

Illustrative walkthrough: how a 'small rash' becomes a border hold

Consider a foreign skincare brand selling through a US reseller. A consumer messages the reseller about a rash after using a peel. The first message sounds routine, so it sits in a customer-service inbox. A week later the consumer reports blistering, emergency treatment, and persistent facial discoloration — facts that may meet the serious-event definition because they involve medical intervention and potentially significant disfigurement. The reseller sends the thread to the brand, but there is no trained intake owner, no case log, and no deadline tracker. No MedWatch report is filed.

Months later, another complaint prompts an FDA inquiry. The brand cannot produce a complete case record, show a seriousness assessment, or explain why the first event was not filed. The label also directs consumers to a contact that no longer works. An incoming shipment now appears to carry a misbranded label while the agency is examining a safety-control failure. The shipment is held, the importer cannot obtain a quick release, and the brand must rebuild records and labels under pressure. What began as one poorly routed complaint now affects inventory, cash flow, and every US sales channel.

The hidden cost is the absence of evidence

A mature adverse-event program does more than submit a form. It proves when a report was received, what follow-up was requested, who assessed seriousness, why a filing decision was made, when the FDA submission occurred, and whether later medical information was captured. Without that evidence, a company cannot show that it met the 15-business-day deadline or applied a consistent standard across cases. The absence of records can turn a defensible product complaint into a broader finding that the compliance system does not exist.

The obligation is inexpensive to meet and expensive to miss

The practical controls are straightforward: one visible intake channel, same-day escalation from resellers and customer service, a structured case record, trained seriousness assessment, a deadline owner, and retained submission evidence. FDABridge's FDA Adverse Event Management service operates those controls for foreign cosmetic brands, including MedWatch Form 3500A filings, follow-up, six-year records, and monthly reporting.